Archive 2018
Group to take comprehensive range of portfolio, efficiency and structural measures
Bayer to strengthen core life science businesses while significantly enhancing productivity and profitability
Third quarter of 2018
Bayer: Good performance in a challenging environment, Group outlook confirmed
Following completion of the divestment of Crop Science businesses to BASF
Bayer: Conditions for beginning Monsanto integration fulfilled
LEO Pharma to expand its lead in medical dermatology with acquisition of Bayer’s prescription dermatology unit
U. S. Department of Justice conditionally approves Bayer’s proposed acquisition of Monsanto